| 王君,刘广一,田聪,等.芪苈强心胶囊对慢性心肾综合征病人心肾功能的影响[J].安徽医药,2021,25(1):132-135. |
| 芪苈强心胶囊对慢性心肾综合征病人心肾功能的影响 |
| Effects of Qili qiangxin capsule on cardiac and renal function in patients with chronic cardiorenal syndrome |
| |
| DOI：10.3969/j.issn.1009?6469.2021.01.033. |
| 中文关键词: 心肾综合征 芪苈强心胶囊 利钠肽，脑 胱抑素 C 心功能 肾功能 |
| 英文关键词: Cardio?renal syndrome Qili qiangxin capsule Natriuretic peptide,brain Cystatin C Cardiac function Renal function |
| 基金项目:廊坊市科学技术局(2018013145) |
|
| 摘要点击次数: 1630 |
| 全文下载次数: 557 |
| 中文摘要: |
| 目的探讨芪苈强心胶囊对慢性心肾综合征病人心肾功能的影响。方法 2018年 3月至 2019年 3月，纳入廊坊市中医医院 100例慢性心肾综合征病人，采用随机数字表法分为治疗组和对照组各 50例，治疗组在西医规范化治疗的基础上配合芪苈强心胶囊，对照组给予单纯西医规范化治疗，疗程 2个月，观察两组病人心功能、肾功能、血浆 N?末端脑钠肽前体(NT?proBNP)及胱抑素 C(CysC)水平与生存质量的变化。结果治疗后，两组左心射血分数(LVEF)、 6 min步行距离显著升高(P＜0.05)与对照组比较，治疗组 LVEF［(49.26±8.23)％比(44.07±7.86)％］、 6 min步行距离［(396.34±68.27)比(365.28±60.35) m］上升幅度，更明显(P＜0.05)；两组血肌酐(Scr)、尿素氮(BUN)、尿微量白蛋白(ALB)显著降低(P＜0.05)，治疗组 Scr［(136.49±21.15)比(178.34±30.01)μmol/L］、 BUN［(6.67±1.21)比(8.02±1.36)mmol/L］、 ALB［(17.81±3.06)比(19.79±3.52)μg/ mL］下降幅度大于对照组(P＜0.05)；两组 NT?proBNP、CysC水平显著降低(P＜0.05)与对照组比较，治疗组 NT?proBNP［(796.31±128.68)比(954.28±160.47)pg/mL］、 CysC［(7.34±1.22)比(9.07±1.69)ng/mL］下降幅，度更大(P＜0.05)；两组明尼苏达心衰生存质量量表(MLHFQ)评分显著降低(P＜0.05)，治疗组 MLHFQ评分［(59.41±10.78)比(66.85±11.92)分］下降幅度大于对照组(P＜0.05)；两组无显著不良反应发生，血、尿常规无明显异常。结论芪苈强心胶囊通过下调 NT?proBNP、CysC表达，可显著改善慢性心肾综合征病人心、肾功能。 |
| 英文摘要: |
| Objective To explore the effects of Qili qiangxin capsule on cardiac function and renal function in patients with chronic cardiorenal syndrome.Methods 100 patients with chronic cardiorenal syndrome in Langfang Hospital of traditional Chi?nese Medicine were enrolled and randomly divided into treatment group and control group by random number table method，with 50 cases in each group.Treatment group was combined with Qili Qiangxin capsule on the basis of standardized treatment of western medicine，and control group was given simple standardized treatment of western medicine，and they had been treated for 2 months. The changes of cardiac function，renal function，levels of plasma NT?proBNP and CysC and quality of life were observed in the two groups.Results After treatment，the LVEF and 6 min walking distance in the two groups significantly increased(P＜0.05).Com? pared with control group，the increases of LVEF［(49.26±8.23)％ vs(44.07±7.86)％］ and 6 min walking distance［(396.34±68.27) m vs.(365.28±60.35)m］were more significant in treatment group(P＜0.05).The Scr［(136.49±21.15)μmol/L vs.(178.34±30.01) μmol/L］，BUN［(6.67±1.21)mmol/L vs.(8.02±1.36)mmol/L］and ALB［(17.81±3.06)μg/mL vs.(19.79±3.52)μg/mL］decreased significantly in the two groups(P＜0.05)，and the decreases of Scr，BUN and ALB in treatment group were greater than those in control group(P＜0.05).The levels of NT?proBNP and CysC in both groups decreased significantly(P＜0.05).Compared with con? trol group，the decreases of NT?proBNP［(796.31±128.68)pg/mL vs.(954.28±160.47)pg/mL］and CysC［(7.34±1.22)ng/mL vs.(9.07±1.69)ng/mL］were greater in treatment group(P＜0.05).The MLHFQ scores in the two groups decreased significantly(P＜ 0.05)，and the decrease of MLHFQ score［(59.41±10.78)scores vs.(66.85±11.92)scores］in treatment group was greater than that in control group(P＜0.05).There were no significant adverse reactions in the two groups，and there were no obvious abnormalities in blood and urine routine.Conclusion Qili Qiangxin capsule can significantly improve the heart and kidney function of patientswith chronic cardiorenal syndrome by down regulating the expression of NT proBNP and CysC. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
